mirtazapine has been researched along with Alcoholism in 14 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine." | 7.91 | Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. ( Bryun, EA; Chumakov, EM; Grishina, EA; Ryzhikova, KA; Skryabin, VY; Smirnov, VV; Sychev, DA; Zastrozhin, MS, 2019) |
| "Mirtazapine was tolerated better than amitriptyline treatment." | 6.73 | Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008) |
| "Major depressive disorder and alcohol dependence are common and serious mental illnesses." | 6.72 | Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. ( Cho, SN; Choi, SB; Hwang, IB; Jeong, YC; Kim, DJ; Kim, JH; Lee, CT; Lee, E; Lee, HK; Lee, YS; Namkoong, K; Oh, DY; Pae, CU; Shin, DH; Shin, YC; Yoon, SJ, 2006) |
| "A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 5.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
| "The objective of the present study was to determine whether a combined psychotherapeutic-psychopharmacological (with mirtazapine) treatment of collateral anxiety and depressive symptomatology during the post-withdrawal phase of alcoholism facilitates the process of alcohol detoxification, which is a decisive stage in the treatment of alcohol-dependent individuals." | 5.11 | Mirtazapine improves alcohol detoxification. ( Christodoulou, G; Liappas, J; Malitas, P; Paparrigopoulos, T; Tzavellas, E, 2004) |
| " The objective of the present study was to investigate: (a) the incidence of social anxiety symptoms in inpatient alcoholics, (b) the effect of alcohol detoxification on these symptoms, and (c) whether a combined psychotherapeutic/mirtazapine treatment during the post-detoxification phase of alcoholism has a greater impact on the aforementioned symptoms than a non-pharmacological approach." | 5.10 | Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. ( Christodoulou, G; Liappas, J; Paparrigopoulos, T; Tzavellas, E, 2003) |
| "The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine." | 3.91 | Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. ( Bryun, EA; Chumakov, EM; Grishina, EA; Ryzhikova, KA; Skryabin, VY; Smirnov, VV; Sychev, DA; Zastrozhin, MS, 2019) |
| "Mirtazapine was tolerated better than amitriptyline treatment." | 2.73 | Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. ( Akdeniz, F; Altintoprak, AE; Coskunol, H; Kitapcioglu, G; Zorlu, N, 2008) |
| "Major depressive disorder and alcohol dependence are common and serious mental illnesses." | 2.72 | Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. ( Cho, SN; Choi, SB; Hwang, IB; Jeong, YC; Kim, DJ; Kim, JH; Lee, CT; Lee, E; Lee, HK; Lee, YS; Namkoong, K; Oh, DY; Pae, CU; Shin, DH; Shin, YC; Yoon, SJ, 2006) |
| "The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms." | 1.62 | Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment. ( Frankle, WG; Lequesne, E; Rohs, A; Zhang, E, 2021) |
| "A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 1.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Greene, MC | 1 |
| Kane, J | 1 |
| Alto, M | 1 |
| Giusto, A | 1 |
| Lovero, K | 1 |
| Stockton, M | 1 |
| McClendon, J | 1 |
| Nicholson, T | 1 |
| Wainberg, ML | 1 |
| Johnson, RM | 1 |
| Tol, WA | 1 |
| Zhang, E | 1 |
| Lequesne, E | 1 |
| Rohs, A | 1 |
| Frankle, WG | 1 |
| Zastrozhin, MS | 1 |
| Skryabin, VY | 1 |
| Smirnov, VV | 1 |
| Grishina, EA | 1 |
| Ryzhikova, KA | 1 |
| Chumakov, EM | 1 |
| Bryun, EA | 1 |
| Sychev, DA | 1 |
| Atigari, OV | 1 |
| Kelly, AM | 1 |
| Jabeen, Q | 1 |
| Healy, D | 1 |
| Gentile, S | 1 |
| Arora, S | 1 |
| Vohora, D | 1 |
| de Witte, LD | 1 |
| Dekker, D | 1 |
| Veraart, J | 1 |
| Kromkamp, M | 1 |
| Kaasjager, K | 1 |
| Vinkers, CH | 1 |
| Holt, C | 1 |
| Butler, S | 1 |
| Agius, M | 1 |
| Zaman, R | 1 |
| Liappas, J | 2 |
| Paparrigopoulos, T | 2 |
| Tzavellas, E | 2 |
| Christodoulou, G | 2 |
| Malitas, P | 1 |
| Crockford, DN | 1 |
| White, WD | 1 |
| Yoon, SJ | 1 |
| Pae, CU | 1 |
| Kim, DJ | 1 |
| Namkoong, K | 1 |
| Lee, E | 1 |
| Oh, DY | 1 |
| Lee, YS | 1 |
| Shin, DH | 1 |
| Jeong, YC | 1 |
| Kim, JH | 1 |
| Choi, SB | 1 |
| Hwang, IB | 1 |
| Shin, YC | 1 |
| Cho, SN | 1 |
| Lee, HK | 1 |
| Lee, CT | 1 |
| Altintoprak, AE | 1 |
| Zorlu, N | 1 |
| Coskunol, H | 1 |
| Akdeniz, F | 1 |
| Kitapcioglu, G | 1 |
| Sommer, M | 1 |
| Dieterich, A | 1 |
| Krause, C | 1 |
| Rüther, E | 1 |
| Wiltfang, J | 1 |
1 review available for mirtazapine and Alcoholism
| Article | Year |
|---|---|
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Topics: Acamprosate; Alcoholism; Amitriptyline; Developing Countries; Disulfiram; Humans; Male; Mirtazapine; | 2023 |
4 trials available for mirtazapine and Alcoholism
| Article | Year |
|---|---|
Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration.
Topics: Adrenergic alpha-Antagonists; Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Inactiva | 2003 |
Mirtazapine improves alcohol detoxification.
Topics: Adolescent; Adult; Alcoholism; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Female; | 2004 |
Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study.
Topics: Adult; Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Female; Human | 2006 |
Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study.
Topics: Adult; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blin | 2008 |
9 other studies available for mirtazapine and Alcoholism
| Article | Year |
|---|---|
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment.
Topics: Adult; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Clozapine; COVID-19; COVID-19 Nuclei | 2021 |
Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
Topics: Adult; Alcoholism; Comorbidity; Cytochrome P-450 CYP2D6; Depressive Disorder; Female; Genotype; Huma | 2019 |
New onset alcohol dependence linked to treatment with selective serotonin reuptake inhibitors.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Substitution; Female; Humans | 2013 |
Pharmacological management of borderline personality disorder in a pregnant woman with a previous history of alcohol addiction: a case report.
Topics: Adult; Alcoholism; Borderline Personality Disorder; Diagnosis, Dual (Psychiatry); Female; Humans; Mi | 2015 |
Comparative Evaluation of Partial α2 -Adrenoceptor Agonist and Pure α2 -Adrenoceptor Antagonist on the Behavioural Symptoms of Withdrawal after Chronic Alcohol Administration in Mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Alcoholism; Animals; Anxiety; Be | 2016 |
[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms].
Topics: Adult; Aggression; Alcoholism; Baclofen; Delirium; Drug Overdose; GABA-B Receptor Agonists; Humans; | 2016 |
An audit to compare patient factors (age, sex, social background & associated physical diagnoses) in people with refractory depression in a Bedfordshire Community Mental Health Team (BCMHT) being augmented with (A) mirtazepine, (B) atypical antipsychotics
Topics: Adult; Age Distribution; Alcoholism; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combine | 2011 |
Mirtazapine for alcohol dependence: a case report.
Topics: Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Humans; Male; Mianse | 2005 |
Subclinical pancreatitis related to mirtazapine - a case report.
Topics: Alcoholism; Amylases; Antidepressive Agents, Tricyclic; Enzymes; Humans; Male; Mianserin; Middle Age | 2001 |